Phase 1 Interstitial Lung Disease Trial, Recruiting NCT03535545 Sponsor: Massachusetts General Hospital Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Phase 1 Interstitial Lung Disease Trial, Recruiting

NCT03535545
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 – Healthy volunteers:

  • You are over 18 years old
  • A doctor or nurse practitioner has confirmed you are in good health based on a physical exam, medical history, and vital signs check
  • You are able to sign a written consent form
  • You have no known history of lung disease (having lung nodules is okay)
  • You have never smoked or used tobacco products

Group 2 – Lung cancer patients:

  • You have been diagnosed with a specific advanced stage of non-small cell lung cancer (stage IIIA) and are a candidate for a combined treatment plan involving chemotherapy, radiation, and surgery
  • You are over 18 years old
  • You are able to sign a written consent form
  • You have not used tobacco in the past 6 months

Group 3 – Pulmonary fibrosis patients:

  • You have been diagnosed with IPF (a specific type of lung scarring) or another form of lung scarring disease, confirmed by certain patterns seen on a CT scan
  • You are between 40 and 80 years old
  • You are able to sign a written consent form
  • You have not used tobacco in the past 6 months

Group 4 – Lung transplant patients with chronic rejection:

  • You have previously had a lung transplant
  • You have been diagnosed with chronic lung allograft dysfunction (a condition where the transplanted lung gradually stops working properly)
  • You are between 40 and 80 years old
  • You are able to sign a written consent form
  • You have not used tobacco in the past 6 months

Group 5 – Patients with lung inflammation from cancer immunotherapy:

  • A CT scan has shown new lung changes (such as cloudiness or scarring) that appeared during or within 3 months of receiving immune checkpoint inhibitor (a type of cancer treatment) therapy
  • You are over 18 years old
  • You are able to sign a written consent form
  • You have not used tobacco in the past 6 months

Who may not be able to join:

  • You have an electrical implant in your body, such as a pacemaker or infusion pump
  • You have any metal implants or fragments in your body, including surgical clips, artificial heart valves with metal parts, shrapnel, or metallic tattoos anywhere on the body or near the eyes
  • You have poor kidney function (for lung transplant patients) or a history of chronic kidney disease (for all other groups)
  • You are currently pregnant or breastfeeding (women who could become pregnant will need a negative pregnancy blood test before joining)
  • You experience severe anxiety or panic in enclosed spaces (claustrophobia)
  • You have already been exposed to a significant amount of radiation through research studies in the past 12 months (confirm with trial site)
  • You are unable to lie still and flat on a scanner bed for the duration of the scan
  • Your body mass index (BMI) is over 33, as this exceeds the weight limit of the scanner table
  • The study doctors have decided for any reason that it would not be safe or appropriate for you to participate
  • You have a known lung disease that does not match the specific conditions being studied, have had pneumonia or a respiratory infection in the past 6 weeks, or have previously had radiation treatment to the chest (unless you are in the lung cancer group)
  • You have had pneumonia or another acute breathing illness within 6 weeks of joining the study (this does not apply to pulmonary fibrosis patients)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sydney B Montesi, MD, Massachusetts General Hospital

Phone: 617 724 4030

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 August 2018
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Ability to detect increased collagen deposition in pulmonary fibrosis.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov